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Implication for health policy/practice/research/medical education:
Although metabolic syndrome (MetS) has been investigated as a potential risk factor for colorectal cancer (CRC) and could be 
a prognostic factor for survival in the patients with CRC, but its effect was not significant and hence the way could be paved for 
decision makers and planners in health system. 
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Introduction
Metabolic syndrome (MetS) may increase the risk of 
colorectal cancer (CRC) through different biological 
mechanisms particularly those that are associated with 
insulin resistance. The underlying mechanism is still 
unknown but hyperinsulinemia could contribute to 
enhancing free or bio-available concentrations of insulin 
(1,2). MetS comprises a variety of risk factors for type 2 
diabetes and cardiovascular diseases, including obesity, 
impaired glucose, hypertension, hypertriglyceridemia, 
and decrease in high density lipoprotein and cholesterol 
levels. Central elements that are associated with MetS and 
obesity, such as hyperinsulinemia and insulin resistance, 
contribute importantly to the process of getting cancerous 
in breast cancer, prostate cancer, endometrial cancer, 
and CRC (3-5). A meta-analysis showed that MetS was 
associated with the increase in the risk of CRC-related 
mortality (2,5). Each year, one million new cases of 
Introduction: Metabolic syndrome (MetS) may affect prognosis of the patients diagnosed 
with colorectal cancer (CRC).
Objectives: This study was aimed to design a model and to examine the prognostic effect of 
MetS on survival time in the patients with CRC.
Patients and Methods: Data were collected from 1127 cases of CRC from Cancer Registry 
Center of the Research Institute of Gastroenterology and Liver Disease, Shahid Beheshti 
University of Medical Sciences, Tehran, Iran. In this cohort study, patients were divided into 
two groups based on the presence of MetS. We tested the prognostic value of MetS in the 
patients by Cox proportional hazard modeling.
Results: Mean ± standard deviation of the patients’ age at diagnosis in MetS group and 
non-MetS group was 56 ± 13 years old and 53 ± 15 years old respectively. Tumor stage as 
an independent variable affected CRC survival. The mean survival time of the MetS and 
non-MetS groups was 23 and 27 months respectively. Independent variables like tumor stage 
(hazard ratio [HR], 1.76; 95% CI, 0.29–0.90) and educational level (HR, 0.50; 95% CI, 0.23–
0.97) had significant effect on CRC survival and MetS (HR, 0.95; 95% CI, 0.52–1.5), tumor size 
(HR, 1.390; 95% CI, 1.237–1.560), family history, age, gender, and smoking had non-significant 
effect on CRC survival.
Conclusion: MetS could be a prognostic factor for survival in the patients with CRC. The 
results suggested that effect of MetS was not significant.
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CRC are diagnosed and 500 000 deaths occur due to its 
worldwide. In the United States CRC is the third leading 
cancer in both genders and the third cancer resulting 
in death, comprising 9% of the whole mortalities from 
cancers (6). According to the cancer registry, CRC 
incidence in five continents varies from 3% in Africa up to 
40% in the United States. In Europe, CRC incidence varies 
from 12.1% in Belarus to 30.5% in Italy (7,8). In addition, 
CRC was the most frequently diagnosed cancer and the 
second common cause of the death from cancers and 
comprised 13% of all new cancer cases in both genders in 
organization for economic cooperation and development 
member countries in 2008. MetS, alongside cardiovascular 
risks, has been offered in some epidemiological studies 
as being associated with several cancers including CRC. 
There is an overlap among risk factors for MetS, diabetes 
mellitus, and CRC (9,10). 
In Iran according to the national cancer registry’s report 
in 2009, acoustic startle response (ASR) of CRC in women 
was 10.89 (ranked as the third) and in men was 11.31 
(ranked as the fifth). In a study carried out by Ansari et al. 
in 2005, in the provinces of Ardabil, Gilan, Mazandaran, 
Golestan, and Kerman, ASR of CRC was 8.2 in men and 
7 in women, which is approximate to the national cancer 
registry’s report (11-13).
Although MetS has been investigated as a potential 
risk factor for CRC (13), various studies have obtained 
conflicting results relevant to MetS-associated CRC risk of 
death. However, a study in China showed that MetS had no 
obvious effect on observable survival and recurrence free 
rate (9,14,15). Several meta-analysis have been conducted 
about association between MetS and CRC and reported 
heterogeneity and homogeneity (2,5,16,17). To the best of 
our knowledge, no study of CRC survival and MetS to date 
has been conducted in Iran (18-20).
Objectives
The aim of this study is to examine whether the MetS is 
associated with survival of the patients with CRC.
Patients and Methods 
The present study is a prospective, cohort one. Data were 
obtained from cancer registry center of the research 
institute of gastroenterology and liver disease, Shahid 
Beheshti University of Medical Sciences, Tehran, Iran. 
The patients from public and private collaborative 
hospitals were treated and referred to the cancer registry. 
This study is based on the data of cancer registry 
including demographic factors (sex, age, education, 
job, etc.), medical records, family history, and diagnosis 
information (symptoms at diagnosis, tumor metastasis, 
grade of tumor, etc.). All patients with CRC diagnosis by 
the pathology report of cancer registry were considered 
as eligible. Finally, 1219 patients (802 [66%] with colon 
cancer, 392 [32%] with rectal cancer, and 25 [2%] with 
unknown cause) were enrolled. The follow-up duration 
was determined from the date of diagnosis up to first of 
October 2008 as the time of the death from the disease 
(as the exact failure time) or survival (as the censoring 
time). First of January 2002 was considered as the start 
time of the study. Deaths were confirmed through calling 
relatives of the patients by telephone. On few (2%) CRC 
patients, no clear information was obtained about the 
cause of death except the date of death; therefore, their 
data were excluded from the analysis. There were 1127 
patients (including 690 men and 437 women) with 
complete follow-up data. These patients were divided into 
two groups based on the presence of MetS. A physician 
interviewed the participants separately, performed a 
physical examination, and obtained a detailed medical 
history. The data were recorded carefully. Body weight 
(kg) and height (m) were measured to compute body 
mass index (BMI). Blood pressure was measured using the 
right arm and a standard mercury sphygmomanometer 
in sitting position after a 5-minute rest, and the mean 
systolic and diastolic blood pressure values of the two 
measurements were recorded. After measurement of 
blood pressure, while the participant was fasting, a venous 
blood sample was taken for determination of the serum 
glucose. For all patients and based on medical file, the 
data on age, sex, smoking, size of the tumor, histological 
type, degree of differentiation (low degree as the referent) 
or tumor, node, metastasis (TNM) stage, and alcohol 
drinking history, separately or in combination, were used 
in the analysis.
Ethical issues
(1) The research followed the tenets of the Declaration 
of Helsinki; (2) informed consent was obtained; (3) the 
research was approved by ethical committee of  Shahid 
Beheshti University of Medical Sciences. This study with 
approval No. 686 issued by Shahid Beheshti University of 
Medical Sciences Ethics Committee was conducted after 
obtaining the informed consent from the patients.
Statistical analysis
Continuous variables in this study were expressed as 
mean ± standard deviation (SD). The variables that 
were statistically significant by univariate analysis were 
included in a multivariate analysis, confirmed by Cox 
regression (Cox proportional hazards model) with 
forward stepwise selection of covariates and with enter 
and remove limits of P values of less than 0.050 and greater 
than 0.100, respectively. Cox proportional hazards model 
was determined as primary mode of analysis, through 
which adjustment for age, smoking, and alcohol drinking 
and other variables was performed. The assumption of 
proportionality of the hazards was tested and found as 
being not violated. In the final model, P values of less 
than 0.05 were considered statistically significant. Stata 12 
software was used for the statistical analysis.
Results
The mean (± SD) follow-up time for the patients with CRC 
was 26 (± 25) months. The mean (± SD) age at diagnosis 
was 54 (± 14) years in CRC patients. Mean (± SD) age 
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at diagnosis was 56 (± 13) years in MetS group and was 
53 (± 15) years in non-MetS. There were non-significant 
differences in the age at diagnosis between the two groups 
(P > 0.060). In the MetS group, 187 tumors were highly 
differentiated, 52 were moderately differentiated, and 13 
were slightly differentiated. In the non-MetS group, 273 
tumors were highly differentiated, 177 were moderately 
differentiated, and 46 were slightly differentiated; no 
significant difference in degree of differentiation was 
observed between the two groups (Chi-square, 0.502; P = 
0 .778). Mean (± SD) size of tumor was 76 (± 9) and 75 
(±13) mm3 in MetS and non-MetS groups, respectively. 
The mean survival time in the MetS and non-MetS groups 
was 23 and 27 months respectively. Survival time was 
shorter in the MetS compared to the non-MetS group. 
Survival curve revealed that survival of the MetS group 
was worse than the non-MetS group. Variables examined 
by univariate analysis for overall survival of CRC included 
sex, age, smoking, size of the tumor, histological type, 
degree of differentiation (low degree as the referent) or 
TNM stage, with MetS (or non-MetS group as the referent), 
family history, education level, alcohol drinking history, 
and marital status. Then variables obtained statistically 
significant by univariate analysis (P < 0.05) were included 
in a multivariate analysis. Independent variables like 
tumor stage (hazard ratio [HR], 1.76; 95% CI, 0.29–0.90) 
and educational level (HR, 0.50; 95% CI, 0.23–0.97) had 
significant effect on CRC survival and MetS (HR, 0.95; 
95% CI, 0.52–1.5), tumor size (HR, 1.390; 95% CI, 1.237–
1.560), family history, age, gender, and smoking had non-
significant effect on CRC survival (Table 1).
Discussion
Cancer is the second leading cause of death in the 
world and is the third leading cause of mortality in Iran. 
Regarding this purpose, we conducted this study on 
1227 Iranian CRC patients to evaluate the effect of MetS 
on survival of CRC. The incidence of MetS is increasing 
due to urbanization, aging, diet structure, and lifestyle 
(21-24). Recent studies show a relationship between diet 
structure and the prevalence of CRC (25,26). However, the 
studies about the association between CRC prognosis and 
MetS have been less conducted. Marrero et al. reported 
a moderate association of post load plasma glucose and 
insulin resistance syndrome with CRC and found that 
the survival rate of breast cancer in the MetS group was 
higher than that of the control group; however, there are 
few reports on the association between MetS and CRC. 
In our study, no obvious differences were observed in 
tumor differentiation between the two groups. Moreover, 
our study showed that the mean survival time of the MetS 
group was shorter than that of the non-MetS group, with 
a statistically non-significant difference. However, results 
of some other studies showed the mean survival time of 
the MetS group was shorter than that of the non-MetS 
group, with a statistically significant difference (16). This 
difference might be due to the definition of MetS or mode 
of survival estimation (i.e. diagnosis to death or treatment 
to death). Shen et al. found that MetS and survival of colon 
cancer were related but MetS had no effect on rectal cancer 
(10). Also, Colangelo et al. reported no association between 
MetS and prognosis of CRC (27,28). The difference in the 
findings could be due to different definitions of MetS and/
or the method of survival estimation (from the diagnosis 
till death or from treatment till death). Furthermore, 
in our multivariate analysis of survival, we found that 
worse TNM stage and size of the tumor were important 
independent risk factors for survival in CRC, which is 
Table 1. Univariate and multivariate Cox model for the effect MetS and its components on survival in colorectal cancer
Characteristics
Hazard Ratio P value 95% CI
Crude Adjusted Univariate Multivariate Univariate Multivariate
MetS
Yes 0.81 0.95 0.05 0.6 0.06-3.78 0.52-1.22
No 1 1
SEX
Male 0.86 1.09 0.3 0.7 0.66-1.4 0.67-1.77
Female 1 1
Marital status
Married 1 1 - - - 0.88-3.49
Single 1.92 1.75 0.004 0.1 1.23-3.0
Education
Illiterate 1 1 1
Primary school 0.68 0.5 0.05 0.03 0.465-1.0 0.26-.94
High school 0.68 0.4 0.07 0.02 0.45-1.05 0.20-0.89
university 0.67 0.6 0.08 0.12 0.43-1.04 0.36-1.2
Tumor grade
grade II 1.46 1.2 0.03 0.4 1.03-2.08 0.73-1.9
III to IV 1.89 2.2 0.01 0.01 1.14-3.33 1.9-4.4
Age at diagnosis 1.03 1.00 0.3 0.9 0.9-1.03 0.98-1.01
Hypertension 0.82 0.83 0.4 0.6 0.5-1.64 0.42-1.64
Diabetes 0.9 1.45 0.7 0.3 0.5-1.64 0.71-2.95
High body mass index 0.71 0.62 0.001 0.006 0.35-6.8 0.44-8.7
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consistent with others’ findings. 
Limitations 
There were some limitations in our study. The information 
gathered about  opoid and drug abuse history and smoking 
was incomplete, based on only two categories of “never” 
and “current or past user”, and qualitative; quantitative 
data about these two factors could yield more exact results. 
There was no data of dietary habit of the patients, as well.
Conclusion
Our study showed that the mean survival time of the 
MetS group was shorter than that of the non-MetS group, 
with a statistically non-significant difference. MetS could 
be a prognostic factor for survival in the patients with 
CRC. The results suggested that effect of MetS was not 
significant.
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